176 related articles for article (PubMed ID: 37213944)
1. Prolonged Survival in a Patient With Extensive-Stage Small Cell Lung Cancer in Spite of Discontinued Immunotherapy With Atezolizumab.
Konishi K; Kuwahara H; Morita D; Imai S; Nagata K
Cureus; 2023 Apr; 15(4):e37757. PubMed ID: 37213944
[TBL] [Abstract][Full Text] [Related]
2. Long-Term Survival and Stable Disease in a Patient with Extensive-Stage Small-Cell Lung Cancer after Treatment with Carboplatin, Etoposide and Atezolizumab.
Bernabé R; Liu SV; Sánchez-Gastaldo A; Alonso García M
Oncol Ther; 2024 Mar; 12(1):175-182. PubMed ID: 38280181
[TBL] [Abstract][Full Text] [Related]
3. Atezolizumab in combination with carboplatin and etoposide for heavily treated small cell lung cancer.
Kataoka N; Kunimatsu Y; Tachibana Y; Sugimoto T; Sato I; Tani N; Ogura Y; Hirose K; Takeda T
Thorac Cancer; 2020 Sep; 11(9):2740-2742. PubMed ID: 32706170
[TBL] [Abstract][Full Text] [Related]
4. Long-term survival in extensive-stage small-cell lung cancer treated with different immune checkpoint inhibitors in multiple-line therapies: A case report and literature review.
Zhang X; Zheng J; Niu Y; Xue C; Yu Y; Tan K; Cui H
Front Immunol; 2022; 13():1059331. PubMed ID: 36532013
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of amrubicin monotherapy after atezolizumab plus carboplatin and etoposide in patients with relapsed small-cell lung cancer.
Imai H; Nagai Y; Minemura H; Tsuda T; Yamada Y; Wasamoto S; Kishikawa T; Shiono A; Shiihara J; Yamaguchi O; Mouri A; Kaira K; Kanazawa K; Taniguchi H; Minato K; Kagamu H
Invest New Drugs; 2022 Oct; 40(5):1066-1079. PubMed ID: 35749041
[TBL] [Abstract][Full Text] [Related]
6. A combined small cell lung carcinoma patient with only small cell carcinoma components in mediastinal lymph node metastasis and chondrosarcoma-like components in liver metastasis.
Kawaguchi T; Yamasaki K; Shigemi S; Dosaka H; Hirosawa R; Nagasawa T; Fujimoto S; Shimajiri S; Yatera K
Respirol Case Rep; 2024 Jun; 12(6):e01416. PubMed ID: 38903949
[TBL] [Abstract][Full Text] [Related]
7. Brief Report: Exploratory Analysis of Maintenance Therapy in Patients With Extensive-Stage SCLC Treated First Line With Atezolizumab Plus Carboplatin and Etoposide.
Reck M; Mok TSK; Mansfield A; De Boer R; Losonczy G; Sugawara S; Dziadziuszko R; Krzakowski M; Smolin A; Hochmair M; Garassino MC; de Castro Junior G; Bischoff H; Lam S; Cardona A; Morris S; Liu SV
J Thorac Oncol; 2022 Sep; 17(9):1122-1129. PubMed ID: 35764236
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of PD-1/PD-L1 inhibitor plus chemotherapy versus chemotherapy alone as first-line treatment for extensive-stage small cell lung cancer: A systematic review and meta-analysis.
Zhang S; Li S; Cheng Y
Thorac Cancer; 2020 Dec; 11(12):3536-3546. PubMed ID: 33058504
[TBL] [Abstract][Full Text] [Related]
9. Real-world evaluation of atezolizumab and etoposide-carboplatin as a first-line treatment for extensive-stage small cell lung cancer.
Kim SH; Jo EJ; Mok J; Lee K; Kim KU; Park HK; Lee MK; Eom JS; Kim MH
Korean J Intern Med; 2023 Mar; 38(2):218-225. PubMed ID: 36800677
[TBL] [Abstract][Full Text] [Related]
10. A phase II study of carboplatin and etoposide plus durvalumab for previously untreated extensive-stage small-cell lung cancer (ES-SCLC) patients with a poor performance status (PS): NEJ045A study protocol.
Asao T; Watanabe S; Tanaka T; Morita S; Kobayashi K
BMC Cancer; 2022 Nov; 22(1):1135. PubMed ID: 36333680
[TBL] [Abstract][Full Text] [Related]
11. Atezolizumab: A Review in Extensive-Stage SCLC.
Frampton JE
Drugs; 2020 Oct; 80(15):1587-1594. PubMed ID: 32990939
[TBL] [Abstract][Full Text] [Related]
12. Immune checkpoint inhibitors: a new landscape for extensive stage small cell lung cancer treatment.
Bianco A; D'Agnano V; Matera MG; Della Gravara L; Perrotta F; Rocco D
Expert Rev Respir Med; 2021 Nov; 15(11):1415-1425. PubMed ID: 34374626
[No Abstract] [Full Text] [Related]
13. Anlotinib plus etoposide and cisplatin/carboplatin as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC): a single-arm, phase II study.
Kong T; Chen L; Zhao X; Duan F; Zhou H; Wang L; Liu D
Invest New Drugs; 2022 Oct; 40(5):1095-1105. PubMed ID: 35788937
[TBL] [Abstract][Full Text] [Related]
14. Adrenal insufficiency in immunochemotherapy for small-cell lung cancer with ectopic ACTH syndrome.
Nakajima H; Niida Y; Hamada E; Hirohito K; Ota M; Okada S; Mohri T; Kurematsu Y; Hontsu S; Muro S; Takahashi Y
Endocrinol Diabetes Metab Case Rep; 2021 Sep; 2021():. PubMed ID: 34582361
[TBL] [Abstract][Full Text] [Related]
15. Investigation of poor predictive factors in extensive stage small cell lung cancer under etoposide-platinum-atezolizumab treatment.
Lim JU; Kang HS; Shin AY; Yeo CD; Kim SK; Kim JW; Kim SJ; Lee SH
Thorac Cancer; 2022 Dec; 13(23):3384-3392. PubMed ID: 36274214
[TBL] [Abstract][Full Text] [Related]
16. Use of Immunotherapy in Extensive-Stage Small Cell Lung Cancer.
Konala VM; Madhira BR; Ashraf S; Graziano S
Oncology; 2020; 98(11):749-754. PubMed ID: 32663833
[TBL] [Abstract][Full Text] [Related]
17. First-line atezolizumab/durvalumab plus platinum-etoposide combined with radiotherapy in extensive-stage small-cell lung cancer.
Li L; Yang D; Min Y; Liao A; Zhao J; Jiang L; Dong X; Deng W; Yu H; Yu R; Zhao J; Shi A
BMC Cancer; 2023 Apr; 23(1):318. PubMed ID: 37024843
[TBL] [Abstract][Full Text] [Related]
18. Atezolizumab plus carboplatin and etoposide in small cell lung cancer patients previously treated with platinum-based chemotherapy.
Ishii H; Azuma K; Kawahara A; Matsuo N; Tokito T; Hoshino T
Invest New Drugs; 2021 Feb; 39(1):269-271. PubMed ID: 32783090
[TBL] [Abstract][Full Text] [Related]
19. Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Wang J; Zhou C; Yao W; Wang Q; Min X; Chen G; Xu X; Li X; Xu F; Fang Y; Yang R; Yu G; Gong Y; Zhao J; Fan Y; Liu Q; Cao L; Yao Y; Liu Y; Li X; Wu J; He Z; Lu K; Jiang L; Hu C; Zhao W; Zhang B; Shi W; Zhang X; Cheng Y;
Lancet Oncol; 2022 Jun; 23(6):739-747. PubMed ID: 35576956
[TBL] [Abstract][Full Text] [Related]
20. Pretreatment glasgow prognostic score predicts survival among patients administered first-line atezolizumab plus carboplatin and etoposide for small cell lung cancer.
Wasamoto S; Imai H; Tsuda T; Nagai Y; Minemura H; Yamada Y; Umeda Y; Kishikawa T; Shiono A; Kozu Y; Shiihara J; Yamaguchi O; Mouri A; Kaira K; Kanazawa K; Taniguchi H; Kaburagi T; Minato K; Kagamu H
Front Oncol; 2022; 12():1080729. PubMed ID: 36741711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
